FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385622011> ?p ?o ?g. }

• W4385622011 abstract "Abstract Background Antifungal prophylaxis can prevent invasive fungal diseases (IFDs) in high-risk, immunocompromised patients. This study assessed the real-world use of mold-active triazoles (MATs) for the prevention of IFDs. Methods This subgroup analysis of a multicenter, observational, prospective registry in the United States from March 2017 to April 2020 included patients who received MATs for prophylaxis (isavuconazole, posaconazole, and voriconazole) at study index/enrollment. The primary objective was to describe patient characteristics and patterns of MAT use. Exploratory assessments included the frequency of breakthrough IFDs and MAT-related adverse drug reactions (ADRs). Results A total of 1177 patients (256 isavuconazole, 397 posaconazole, 272 voriconazole, and 252 multiple/sequenced MATs at/after index/enrollment) were included in the prophylaxis subgroup analysis. Patient characteristics were similar across MAT groups, but risk factors varied. Hematological malignancy predominated (76.5%) across all groups. Breakthrough IFDs occurred in 7.1% (73/1030) of patients with an investigator's assessment (5.0% [11/221] isavuconazole; 5.3% [20/374] posaconazole; 4.0% [9/226] voriconazole; and 15.8% [33/209] multiple/sequenced MATs). Aspergillus (29.5% [18/61]) and Candida (36.1% [22/61]) species were the most common breakthrough pathogens recovered. ADRs were reported in 14.1% of patients, and discontinuation of MATs due to ADRs was reported in 11.1% of patients (2.0% [5/245] isavuconazole; 8.2% [30/368] posaconazole; and 10.1% [27/267] voriconazole). Conclusions Breakthrough IFDs were uncommon in patients who received MATs for prophylaxis. Candida and Aspergillus species were the most commonly reported breakthrough pathogens. The discontinuation of MATs due to ADRs was infrequent. These findings support prophylactic strategies with isavuconazole, posaconazole, and voriconazole in high-risk patients." @default.
• W4385622011 created "2023-08-08" @default.
• W4385622011 creator A5002306472 @default.
• W4385622011 creator A5004504427 @default.
• W4385622011 creator A5004769805 @default.
• W4385622011 creator A5036789267 @default.
• W4385622011 creator A5041785705 @default.
• W4385622011 creator A5046242349 @default.
• W4385622011 creator A5048975944 @default.
• W4385622011 creator A5063196803 @default.
• W4385622011 creator A5066774127 @default.
• W4385622011 creator A5071800632 @default.
• W4385622011 date "2023-08-07" @default.
• W4385622011 modified "2023-09-23" @default.
• W4385622011 title "Real-World use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results from a Subgroup Analysis of a Multicenter National Registry" @default.
• W4385622011 cites W1540152692 @default.
• W4385622011 cites W16689404 @default.
• W4385622011 cites W1988385266 @default.
• W4385622011 cites W1989345554 @default.
• W4385622011 cites W2033083410 @default.
• W4385622011 cites W2035069664 @default.
• W4385622011 cites W2091078373 @default.
• W4385622011 cites W2166734004 @default.
• W4385622011 cites W2175975424 @default.
• W4385622011 cites W2278074394 @default.
• W4385622011 cites W2470291098 @default.
• W4385622011 cites W2518295018 @default.
• W4385622011 cites W2886222856 @default.
• W4385622011 cites W2920115754 @default.
• W4385622011 cites W2924814601 @default.
• W4385622011 cites W2937526073 @default.
• W4385622011 cites W2956099843 @default.
• W4385622011 cites W2963834434 @default.
• W4385622011 cites W3014682401 @default.
• W4385622011 cites W3031421306 @default.
• W4385622011 cites W3092750903 @default.
• W4385622011 cites W3165576900 @default.
• W4385622011 cites W4200111432 @default.
• W4385622011 cites W4221058758 @default.
• W4385622011 cites W4282824303 @default.
• W4385622011 cites W4283071696 @default.
• W4385622011 doi "https://doi.org/10.1093/ofid/ofad424" @default.
• W4385622011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37674634" @default.
• W4385622011 hasPublicationYear "2023" @default.
• W4385622011 type Work @default.
• W4385622011 citedByCount "0" @default.
• W4385622011 crossrefType "journal-article" @default.
• W4385622011 hasAuthorship W4385622011A5002306472 @default.
• W4385622011 hasAuthorship W4385622011A5004504427 @default.
• W4385622011 hasAuthorship W4385622011A5004769805 @default.
• W4385622011 hasAuthorship W4385622011A5036789267 @default.
• W4385622011 hasAuthorship W4385622011A5041785705 @default.
• W4385622011 hasAuthorship W4385622011A5046242349 @default.
• W4385622011 hasAuthorship W4385622011A5048975944 @default.
• W4385622011 hasAuthorship W4385622011A5063196803 @default.
• W4385622011 hasAuthorship W4385622011A5066774127 @default.
• W4385622011 hasAuthorship W4385622011A5071800632 @default.
• W4385622011 hasBestOaLocation W43856220111 @default.
• W4385622011 hasConcept C126322002 @default.
• W4385622011 hasConcept C16005928 @default.
• W4385622011 hasConcept C187960798 @default.
• W4385622011 hasConcept C197934379 @default.
• W4385622011 hasConcept C203014093 @default.
• W4385622011 hasConcept C2776391196 @default.
• W4385622011 hasConcept C2778566413 @default.
• W4385622011 hasConcept C2778715236 @default.
• W4385622011 hasConcept C2779175654 @default.
• W4385622011 hasConcept C2779548794 @default.
• W4385622011 hasConcept C2780690907 @default.
• W4385622011 hasConcept C71924100 @default.
• W4385622011 hasConcept C86803240 @default.
• W4385622011 hasConcept C89423630 @default.
• W4385622011 hasConcept C95190672 @default.
• W4385622011 hasConceptScore W4385622011C126322002 @default.
• W4385622011 hasConceptScore W4385622011C16005928 @default.
• W4385622011 hasConceptScore W4385622011C187960798 @default.
• W4385622011 hasConceptScore W4385622011C197934379 @default.
• W4385622011 hasConceptScore W4385622011C203014093 @default.
• W4385622011 hasConceptScore W4385622011C2776391196 @default.
• W4385622011 hasConceptScore W4385622011C2778566413 @default.
• W4385622011 hasConceptScore W4385622011C2778715236 @default.
• W4385622011 hasConceptScore W4385622011C2779175654 @default.
• W4385622011 hasConceptScore W4385622011C2779548794 @default.
• W4385622011 hasConceptScore W4385622011C2780690907 @default.
• W4385622011 hasConceptScore W4385622011C71924100 @default.
• W4385622011 hasConceptScore W4385622011C86803240 @default.
• W4385622011 hasConceptScore W4385622011C89423630 @default.
• W4385622011 hasConceptScore W4385622011C95190672 @default.
• W4385622011 hasFunder F4320323024 @default.
• W4385622011 hasFunder F4320332563 @default.
• W4385622011 hasIssue "9" @default.
• W4385622011 hasLocation W43856220111 @default.
• W4385622011 hasLocation W43856220112 @default.
• W4385622011 hasOpenAccess W4385622011 @default.
• W4385622011 hasPrimaryLocation W43856220111 @default.
• W4385622011 hasRelatedWork W2069764483 @default.
• W4385622011 hasRelatedWork W2156467521 @default.
• W4385622011 hasRelatedWork W2264943376 @default.
• W4385622011 hasRelatedWork W2750285914 @default.
• W4385622011 hasRelatedWork W3002123419 @default.

• next